Clinical Development Services
AB2 Bio has developed the first and proprietary assay to detect and measure free IL-18 in body fluids, which gives us the capability of identifying diseases associated with free IL-18 levels. The assay could also be used as a companion diagnostic to select patients most likely to respond to treatment with IL-18BP.
-
Most popular related searches
Services Overview
AB2 Bio is pioneering an empirical therapeutic approach to a rational selection of medical targets. If patients with high levels of free IL-18 can be identified, the clinical impact of treatment with IL-18BP will be maximized, while those patients unlikely to respond will not be unnecessarily exposed to ineffective medicines. Such an approach will reduce regulatory hurdles and increase the chances of successful clinical trials.
Extensive Phase I, Ib and II clinical trial results demonstrated that recombinant human IL-18BP is very well tolerated and has an excellent safety profile.
Customer reviews
No reviews were found for Clinical Development Services. Be the first to review!